Prophylactic administration of tirofiban prevents ischemic events in endovascular treatment of unruptured intracranial aneurysms.

Jinbiao Yao, Yangyang Zhou, Ruhang Xie, Chao Wang, Yongnan Zhu, Wenqiang Li, Ying Zhang

Abstract read

In one paragraph

Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinbiao Yao *Department of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0001-9685-5879

Yangyang Zhou *Department of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Ruhang XieDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Chao WangDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Yongnan ZhuNeurosurgery, Beijing Geriatric Hospital, Beijing, China.

Wenqiang LiDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. lwqsurgeon@163.com.

Ying ZhangDepartment of Interventional Neuroradiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. yingzhang829@163.com.ORCID http://orcid.org/0000-0002-5812-372X

Funding

Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes JYY2023-5Capital's Funds for Health Improvement and Research 2022-1-2041Summit Talent Program DFL20220504

6 · The paper itself

Abstract

backgroundStents-assisted coiling (SAC) and flow diverters (FD) are widely used in the endovascular treatment of intracranial aneurysms. However, due to the thrombogenicity of metallic implants, their application may increase the risk of ischemic events. This study aims to evaluate the efficacy of prophylactic tirofiban with dual antiplatelet treatment (DAPT) in unruptured intracranial aneurysms (UIA) patients treated with SAC or FD.

methodsThis single center retrospective study included patients with UIAs treated with SAC or FD. Data collected included demographic information, imaging findings, laboratory results, and perioperative complications. Multivariate logistic regression analysis was used to identify independent risk factors for ischemic events. Patients were stratified based on these risk factors, and the efficacy of tirofiban was evaluated across different risk groups.

resultsA total of 420 patients were included in the study, of whom 22(5.2%) experienced ischemic events. Among them, eight patients (3.3%) were in the tirofiban group and 14 patients (8.0%) were in the DAPT (non-tirofiban) group. Multivariate logistic regression identified independent risk factors for ischemic events, including posterior circulation aneurysm (OR: 2.87, 95% CI: 1.06-7.78; P = 0.038) and diabetes (OR: 4.05, 95% CI: 1.50-10.96; P = 0.006). The prophylactic use of tirofiban combined with DAPT can effectively reduce postoperative ischemic events (OR: 0.35, 95% CI: 0.14-0.91; P = 0.032) without increasing the risk of hemorrhage.

conclusionThis study demonstrates that prophylactic use of tirofiban can effectively reduce postoperative ischemic events in UIA patients receiving SAC or FD treatments without increasing the risk of hemorrhage.

Indexed as

Brain IschemiaEndovascular ProceduresIntracranial AneurysmPlatelet Aggregation InhibitorsTirofibanAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsStentsTreatment OutcomePlatelet Aggregation InhibitorsTirofibanEndovascular treatmentFlow diverterIntracranial aneurysmIschemic eventStentTirofban

Identifiers

PMID40410393

DOI10.1016/j.jacc.2010.03.100

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.